Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this research study is to find out if a certain type of hormone therapy, gonadotropin-releasing hormone agonist (GnRH agonist), affects the way the body produces and responds to insulin. The investigators will evaluate the changes in insulin sensitivity during and after GnRH agonist treatment for prostate cancer. The investigators are assessing the possibility that treatment-related insulin resistance may contribute to the risk of diabetes and/or cardiovascular disease in men with prostate cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Institutes of Health (NIH)
• Treatments: Hormones; Insulin

Criteria

Inclusion Criteria:

• Adenocarcinoma of the prostate, clinical stage M0

• Scheduled to initiate GnRH agonist therapy with intended treatment duration of greater than 24 months (Group A)

• Scheduled for radiation therapy and neoadjuvant GnRH agonist therapy with intended 6 month duration of treatment (Group B)

• Karnofsky Performance Status 90 or 100

• Local or local-regional disease (Group B)

Exclusion Criteria:

• Prior hormone therapy (GnRH agonist or antiandrogen)

• History of bilateral orchiectomy

• Known diabetes mellitus or glucose intolerance

• Current treatment with anabolic agents or metabolic agents known to affect insulin or glucose levels